Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
Abstract Objectives This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF). Methods A prospective observational study was conducted from May 2022 to May 2023, focusi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-025-04477-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863257381732352 |
|---|---|
| author | Yinge Zhan Liu Li Jie Zhou Yishan Ma Xuchong Guan Suo Wang Ya Chang |
| author_facet | Yinge Zhan Liu Li Jie Zhou Yishan Ma Xuchong Guan Suo Wang Ya Chang |
| author_sort | Yinge Zhan |
| collection | DOAJ |
| description | Abstract Objectives This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF). Methods A prospective observational study was conducted from May 2022 to May 2023, focusing on patients with HFrEF admitted to our hospital. Eligible patients were sequentially numbered and enrolled based on specific inclusion and exclusion criteria. They were divided into two groups: one receiving standard heart failure therapy and the other receiving standard therapy plus Vericiguat. Data were collected at baseline and at 1, 3, and 6 months post-discharge, including NT-proBNP, sST2, and echocardiographic assessments. All patients underwent CPET before discharge and again six months post-discharge for within-subject comparisons. Results The study enrolled 158 patients, with 79 in each treatment arm. No significant baseline differences were observed in the Weber Functional Classification or CPET parameters. At six months, the Vericiguat group exhibited a significant reduction in patients classified as C (from 31.6 to 7.5%) and D (from 31.6 to 3.7%), with P values less than 0.05. Additionally, Vericiguat significantly improved Peak Oxygen Consumption (from 14.24 ± 6.21 to 19.03 ± 4.87 ml/kg/min) and Anaerobic Threshold (from 10.48 ± 3.82 to 13.48 ± 3.31 ml/kg/min). Compared to the standard treatment group, the Vericiguat group demonstrated significantly higher Peak Oxygen Consumption, Anaerobic Threshold, and a lower Carbon Dioxide Equivalent Slope, with P values all below 0.05. Conclusions Vericiguat safely enhances exercise tolerance, as evaluated by CPET, in high-risk patients with HFrEF. |
| format | Article |
| id | doaj-art-2fb3b421ce484b6e84dedf84b27618a0 |
| institution | Kabale University |
| issn | 1471-2261 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj-art-2fb3b421ce484b6e84dedf84b27618a02025-02-09T12:11:14ZengBMCBMC Cardiovascular Disorders1471-22612025-02-0125111010.1186/s12872-025-04477-2Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational studyYinge Zhan0Liu Li1Jie Zhou2Yishan Ma3Xuchong Guan4Suo Wang5Ya Chang6Department of Cardiovascular Medicine, The First Hospital of Hebei Medical UniversityDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical UniversityDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical UniversityDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical UniversityDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical UniversityDepartment of Cardiovascular Medicine, Shijiazhuang People’s HospitalDepartment of Cardiovascular Medicine, The First Hospital of Hebei Medical UniversityAbstract Objectives This study aims to evaluate the therapeutic effect of Vericiguat through cardiopulmonary exercise testing (CPET) in patients with chronic heart failure and reduced ejection fraction (HFrEF). Methods A prospective observational study was conducted from May 2022 to May 2023, focusing on patients with HFrEF admitted to our hospital. Eligible patients were sequentially numbered and enrolled based on specific inclusion and exclusion criteria. They were divided into two groups: one receiving standard heart failure therapy and the other receiving standard therapy plus Vericiguat. Data were collected at baseline and at 1, 3, and 6 months post-discharge, including NT-proBNP, sST2, and echocardiographic assessments. All patients underwent CPET before discharge and again six months post-discharge for within-subject comparisons. Results The study enrolled 158 patients, with 79 in each treatment arm. No significant baseline differences were observed in the Weber Functional Classification or CPET parameters. At six months, the Vericiguat group exhibited a significant reduction in patients classified as C (from 31.6 to 7.5%) and D (from 31.6 to 3.7%), with P values less than 0.05. Additionally, Vericiguat significantly improved Peak Oxygen Consumption (from 14.24 ± 6.21 to 19.03 ± 4.87 ml/kg/min) and Anaerobic Threshold (from 10.48 ± 3.82 to 13.48 ± 3.31 ml/kg/min). Compared to the standard treatment group, the Vericiguat group demonstrated significantly higher Peak Oxygen Consumption, Anaerobic Threshold, and a lower Carbon Dioxide Equivalent Slope, with P values all below 0.05. Conclusions Vericiguat safely enhances exercise tolerance, as evaluated by CPET, in high-risk patients with HFrEF.https://doi.org/10.1186/s12872-025-04477-2VericiguatHeart failure with reduced ejection fractionCardiopulmonary exercise testing |
| spellingShingle | Yinge Zhan Liu Li Jie Zhou Yishan Ma Xuchong Guan Suo Wang Ya Chang Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study BMC Cardiovascular Disorders Vericiguat Heart failure with reduced ejection fraction Cardiopulmonary exercise testing |
| title | Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study |
| title_full | Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study |
| title_fullStr | Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study |
| title_full_unstemmed | Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study |
| title_short | Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study |
| title_sort | efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction a prospective observational study |
| topic | Vericiguat Heart failure with reduced ejection fraction Cardiopulmonary exercise testing |
| url | https://doi.org/10.1186/s12872-025-04477-2 |
| work_keys_str_mv | AT yingezhan efficacyofvericiguatinpatientswithchronicheartfailureandreducedejectionfractionaprospectiveobservationalstudy AT liuli efficacyofvericiguatinpatientswithchronicheartfailureandreducedejectionfractionaprospectiveobservationalstudy AT jiezhou efficacyofvericiguatinpatientswithchronicheartfailureandreducedejectionfractionaprospectiveobservationalstudy AT yishanma efficacyofvericiguatinpatientswithchronicheartfailureandreducedejectionfractionaprospectiveobservationalstudy AT xuchongguan efficacyofvericiguatinpatientswithchronicheartfailureandreducedejectionfractionaprospectiveobservationalstudy AT suowang efficacyofvericiguatinpatientswithchronicheartfailureandreducedejectionfractionaprospectiveobservationalstudy AT yachang efficacyofvericiguatinpatientswithchronicheartfailureandreducedejectionfractionaprospectiveobservationalstudy |